Colossal Biosciences CEO Ben Lamm Defends Trump Administration Collaboration
The biotech firm leverages political alignment to advance controversial de-extinction and biobanking initiatives.
1Strategic Political Alignment
Colossal Biosciences CEO Ben Lamm claims the Trump administration supports their initiatives because they prioritize technology, profitability, and high-profile wins. Despite the administration's historically lukewarm stance on conservation, Lamm successfully secured support for a biobanking project. This partnership aims to collect DNA samples from endangered species to prevent further biodiversity loss.
2Ambitious Financial Targets
The company recently raised 230 million dollars in a Series C round, achieving a valuation of 10.2 billion dollars. Reports indicate Colossal is currently seeking a new funding round that could push its valuation between 20 and 30 billion dollars. These funds support diverse ventures, including plastic-destroying microbes and military-grade canine enhancements.
3Military Canine Development
Colossal holds a stake in Warhound, a startup co-developed with Anduril CEO Palmer Luckey. The venture focuses on creating genetically enhanced dogs for military, law enforcement, and first responder roles. Lamm argues this approach reduces reliance on European puppy mills, aiming to standardize the quality and health of working animals through biotechnology.
4Conservationist Criticisms Persist
Critics argue that Colossal’s focus on de-extinction distracts from urgent, real-world efforts to protect currently endangered species. Conservationists fear that promising future technological solutions may weaken political will for immediate habitat protection. Lamm rejects these claims, asserting that ignoring biodiversity crises for political reasons is not a viable long-term strategy.
5Scientific Substance Debates
The company faces scrutiny regarding the scientific accuracy of its claims. Experts noted that the dire wolves created by Colossal are genetically very similar to existing gray wolves. While critics label these announcements as style over substance, Lamm maintains that the company has actually undersold its progress in complex gene-editing research.
6Mammoth Project Timeline
Colossal will miss its original 2028 deadline for producing a wooly mammoth. Despite the delay, Lamm reports significant technical progress, including 130 specific edits to mammoth genes. He remains indifferent to whether the final product is classified as a true mammoth or simply a genetically modified hairy elephant for public perception.
7Boundaries of De-extinction
While the company explores various genetic revivals, Lamm clarified that extinct ocean predators like the megalodon are not on the agenda. Despite receiving significant public and investor interest in reviving such massive creatures, the company has officially ruled out the project, focusing instead on terrestrial species and broader biobanking efforts.
8Future Operational Outlook
Lamm promises more surprise and delight moments as the company continues its gene-editing work. By balancing high-valuation fundraising with controversial scientific goals, Colossal remains a polarizing force in biotechnology. The firm's ability to maintain political and financial support will determine if these ambitious genetic projects eventually transition into tangible, scalable realities.